About Kieren Marr
Form D filings for Elion Therapeutics in 2024 list Kieren Marr as executive officer and director.
Form D filings also name Kieren Marr as a founder and president at Pearl Diagnostics and sits on its board.
Kieren Marr first appears on SEC filings in 2022.
Experience
This experience comes from Kieren Marr's profile and from SEC filings. For roles taken from filings, the years are when the filings name Kieren Marr in the role, so the role may have started earlier or lasted longer.
Elion Therapeutics, Inc. Current
Co-founder & Chief Executive Officer (2022 – Present)
Director
2022 – Present · New York, NY
TU
The Johns Hopkins University Current
Adjunct Professor of Medicine and Business
2022 – Present
Pearl Diagnostics, Inc. Current
Founder and President, director
Founder & Director (2014 – Present)
2014 – Present · Baltimore, MD
Urine tests help clinicians diagnose lung infections.
LC
Life Sciences Consulting Current
Founder
2013 – Present
ST
Sfunga Therapeutics
Chief Medical Officer
2022 – 2024
MT
MycoMed Technologies
Chief Executive Officer
2014 – 2022
JU
Johns Hopkins University
Professor of Medicine, Oncology and Business
2008 – 2021
FC
Fred Hutchinson Cancer Research Center
Associate Member
1999 – 2007
UW
University of Washington
Associate Professor
1999 – 2007
Key Colleagues at Startups
The people Kieren Marr works with at each company, as listed on that company's latest Form D.
Pearl Diagnostics, Inc. · Form D, Apr 21, 2026
Elion Therapeutics, Inc. · Form D, Jun 26, 2024